Twinbeech Capital LP Sells 58,223 Shares of Merck & Co., Inc. (NYSE:MRK)

Twinbeech Capital LP trimmed its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 52.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 52,269 shares of the company's stock after selling 58,223 shares during the quarter. Twinbeech Capital LP's holdings in Merck & Co., Inc. were worth $5,200,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in MRK. Janney Montgomery Scott LLC raised its holdings in Merck & Co., Inc. by 1.9% during the 4th quarter. Janney Montgomery Scott LLC now owns 1,902,509 shares of the company's stock valued at $189,262,000 after buying an additional 35,525 shares during the last quarter. Napatree Capital LLC raised its holdings in Merck & Co., Inc. by 13.0% during the 4th quarter. Napatree Capital LLC now owns 4,220 shares of the company's stock valued at $420,000 after buying an additional 485 shares during the last quarter. Littlejohn Financial Services Inc. bought a new stake in Merck & Co., Inc. during the 4th quarter valued at $2,080,000. Raab & Moskowitz Asset Management LLC raised its holdings in Merck & Co., Inc. by 17.7% during the 4th quarter. Raab & Moskowitz Asset Management LLC now owns 56,307 shares of the company's stock valued at $5,601,000 after buying an additional 8,461 shares during the last quarter. Finally, Global Wealth Management Investment Advisory Inc. raised its holdings in Merck & Co., Inc. by 102.2% during the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 45,057 shares of the company's stock valued at $4,482,000 after buying an additional 22,775 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Insider Transactions at Merck & Co., Inc.

In other news, SVP Dalton E. Smart III sold 4,262 shares of the company's stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $82.76, for a total value of $352,723.12. Following the sale, the senior vice president now directly owns 7,778 shares of the company's stock, valued at $643,707.28. This represents a 35.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.13% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on MRK shares. Guggenheim reiterated a "buy" rating and set a $115.00 price target on shares of Merck & Co., Inc. in a report on Thursday, April 17th. Morgan Stanley lowered their price target on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Deutsche Bank Aktiengesellschaft lowered shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and lowered their price target for the company from $128.00 to $105.00 in a report on Tuesday, February 18th. TD Securities lowered shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and lowered their price target for the company from $121.00 to $100.00 in a report on Monday, February 10th. Finally, Bank of America lowered their price target on shares of Merck & Co., Inc. from $118.00 to $112.00 and set a "buy" rating for the company in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $109.19.

Merck & Co., Inc. Stock Up 0.9%

NYSE:MRK opened at $77.92 on Wednesday. The firm's 50-day moving average price is $82.80 and its 200-day moving average price is $91.89. The company has a market capitalization of $195.66 billion, a PE ratio of 11.58, a P/E/G ratio of 0.77 and a beta of 0.43. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $134.63.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $2.22 earnings per share for the quarter, topping analysts' consensus estimates of $2.16 by $0.06. The firm had revenue of $15.53 billion for the quarter, compared to the consensus estimate of $15.59 billion. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The company's revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.07 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. announced that its Board of Directors has approved a stock buyback plan on Tuesday, January 28th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 4.1% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's board believes its stock is undervalued.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.